天士力(600535.SH)半年度淨利潤降2.86%至8.99億元
格隆匯8月21日丨天士力(600535.SH)發佈2019年半年度報告，實現營業收入94.17億元，同比增長11.10%；歸屬於上市公司股東的淨利潤8.99億元，同比下降2.86%；歸屬於上市公司股東的扣除非經常性損益的淨利潤8.36億元，同比增長0.44%；基本每股收益0.5957元。
2019年上半年，面對醫藥行業的挑戰與機遇，公司持續聚焦市場最大、發展最快的心腦血管、消化代謝、抗腫瘤三大治療領域，通過創新藥物佈局和在研產品有序推進，提升未來發展動能；通過組織變革與管理優化，提升運營效率和管控能力。報告期內，公司實現了現代中藥、生物藥、化學藥的協同發展，繼續保持在中國心腦血管市場創新藥領域的領先優勢。
生物藥板塊分拆赴港上市項目順利進行:報告期內子公司天士力生物醫藥股份有限公司收到了中國證監會出具的《行政許可申請受理單》(“小路條”)，並已向香港聯交所遞交了發行上市申請，未來將憑藉香港資本市場的優勢為公司創新藥的研發與國際化提供資源保障。在研管線有序推進：止動顆粒、複方丹蔘滴丸增加糖網適應症申報生產；普佑克缺血性腦卒中適應症III期臨牀試驗快速順利推進；1.1類化學藥DPP-4抑制劑和1類生物藥T601溶瘤病毒獲批臨牀。
公司通過不斷創新精準營銷、強化產品臨牀價值，繼續保持產品的競爭優勢。報告期內，公司實現醫藥工業銷售收入33.08億元，佔公司主營業務收入35.28%。
天士營銷通過加強應收賬款指標管控、進行連鎖運營價值評估等舉措，進一步強化資金管控，提升運營能力。報告期內，公司醫藥商業板塊銷售收入60.70億元，佔公司主營業務收入64.72%。
公司快速推進四位一體的藥物研發國際化戰略，穩步推進現代中藥、生物藥、化學藥三大研發平台75個管線品種取得多項進展，其中43款藥品(其中含仿製藥一致性評價9款藥物)已進入臨牀階段。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app！
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
